These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16898269)

  • 21. Cytotoxic effects of pemetrexed in gastric cancer cells.
    Kim JH; Lee KW; Jung Y; Kim TY; Ham HS; Jong HS; Jung KH; Im SA; Kim TY; Kim NK; Bang YJ
    Cancer Sci; 2005 Jun; 96(6):365-71. PubMed ID: 15958060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Yazawa Y; Tsunoda S; Furukawa Y
    Oncol Res; 2000; 12(3):137-48. PubMed ID: 11216672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed.
    Min SH; Goldman ID; Zhao R
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):819-27. PubMed ID: 17594092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases.
    Bischof M; Huber P; Stoffregen C; Wannenmacher M; Weber KJ
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):289-92. PubMed ID: 12909245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
    Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
    BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
    Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
    Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
    Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro.
    Akutsu M; Kano Y; Tsunoda S; Suzuki K; Yazawa Y; Miura Y
    Eur J Cancer; 1995 Dec; 31A(13-14):2341-6. PubMed ID: 8652267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.
    Mercalli A; Sordi V; Formicola R; Dandrea M; Beghelli S; Scarpa A; Di Carlo V; Reni M; Piemonti L
    Br J Cancer; 2007 May; 96(9):1358-67. PubMed ID: 17426706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.
    Su L; Liu G; Hao X; Zhong N; Zhong D; Liu X; Singhal S
    Eur J Cancer; 2011 Nov; 47(16):2471-8. PubMed ID: 21726997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alimta (pemetrexed disodium): a multitargeted antifolate for the treatment of mesothelioma.
    Green MR
    Lung Cancer; 2002 Nov; 38 Suppl 2():S55-7. PubMed ID: 12431831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA drug approval summaries: pemetrexed (Alimta).
    Hazarika M; White RM; Johnson JR; Pazdur R
    Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
    Dundar Y; Bagust A; Dickson R; Dodd S; Green J; Haycox A; Hill R; McLeod C; Walley T
    Health Technol Assess; 2007 Jan; 11(1):1-90. PubMed ID: 17181984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
    Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
    Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.